Bottom line
XLV vs IXJ: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and IXJ (iShares Global Healthcare ETF) share a meaningful slice of their top holdings — about 76% by weight.
XLV is cheaper at 0.08% vs 0.38% — a difference of $30 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +6.4% for IXJ.
Updated Nov 19, 2026
XLV vs IXJ side by side
| XLV | IXJ | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.38% |
| Annual cost per $10k | $8 | $38 |
| 10-yr cost on $10k (prospectus) | $103 | $480 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +14.9% |
| 5-yr return (annualized) | +8.1% | +6.4% |
| 10-yr return (annualized) | +9.8% | +8.2% |
| Best quarter | +14.5% | +13.6% |
| Worst quarter | −12.7% | −11.8% |
| Net assets (fund) | $40.6B | $3.8B |
| Number of holdings | 65 | 124 |
| Portfolio turnover | 2% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | IXJ | Difference |
|---|---|---|---|
| 2025 | +14.5% | +14.9% | −0.3% |
| 2024 | +2.5% | +0.6% | +1.9% |
| 2023 | +2.0% | +3.5% | −1.5% |
| 2022 | −2.1% | −4.7% | +2.6% |
| 2021 | +25.9% | +19.5% | +6.4% |
| 2020 | +13.3% | +12.5% | +0.8% |
| 2019 | +20.7% | +23.4% | −2.7% |
| 2018 | +6.3% | +2.9% | +3.4% |
| 2017 | +21.7% | +20.3% | +1.4% |
| 2016 | −2.8% | −6.2% | +3.4% |
Source: Fund prospectus bar charts
Holdings overlap
18 of XLV's top 25 holdings also appear in IXJ's top 25.
| Holding | XLV | IXJ |
|---|---|---|
| Eli Lilly & Co | 16.51% | 10.93% |
| Johnson & Johnson | 10.64% | 7.04% |
| AbbVie Inc | 7.74% | 5.12% |
| UnitedHealth Group Inc | 6.57% | 4.40% |
| Merck & Co Inc | 5.52% | 4.12% |
| Amgen Inc | 3.40% | 2.54% |
| Thermo Fisher Scientific Inc | 3.24% | 2.42% |
| Abbott Laboratories | 2.75% | 2.05% |
| Gilead Sciences Inc | 2.73% | 2.04% |
| Intuitive Surgical Inc | 2.45% | 1.83% |
| Pfizer Inc | 2.39% | 1.78% |
| CVS Health Corp | 2.30% | 1.71% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.64% |
| Danaher Corp | 2.09% | 1.56% |
| Bristol-Myers Squibb Co | 2.05% | 1.53% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
FAQ
What is the difference between XLV and IXJ?
Which is cheaper, XLV or IXJ?
Should I own both XLV and IXJ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.